October 9, 2018

UConn licenses IP to New Haven’s Biohaven

UConn has authorized New Haven's Biohaven Pharmaceutical Holding Co. Ltd. to study and develop an antibody it developed that fights autoimmune disorders.

Connecticut's flagship state university says it signed a license agreement to provide Biohaven intellectual property rights to develop the antibody UC1MT, which targets extracellular metallothionein (MT), a stress response protein that has been shown to develop autoimmune and inflammatory diseases.

The university and Biohaven also signed a collaborative research agreement to continue exploring the role MT plays.

Under the license agreement, Biohaven is granted exclusive acquisition rights for a worldwide license of UC1MT and its patents for development and commercialization throughout the world.

The antibody was discovered by professor Michael Lynes, UConn's department head for molecular and cell biology.

Lynes said the agreement is a "critical" step for his research group in their effort to "define the path for taking our basic research discoveries into the clinic."

"I believe we have an exciting opportunity to develop this new approach to the management of important inflammatory and autoimmune diseases where metallothionein plays a significant role," he said.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Can CT balance its next two-year budget, projected to have a $4 billion-plus deficit, without raising taxes? <>
Most Popular on Facebook
Copyright 2017 New England Business Media